XNAS:REGN Regeneron Pharmaceuticals Inc Insider Activity 4 Filing - 2/23/2012

Effective Date 2/23/2012

XNAS:REGN Fair Value Estimate
Premium
XNAS:REGN Consider Buying
Premium
XNAS:REGN Consider Selling
Premium
XNAS:REGN Fair Value Uncertainty
Premium
XNAS:REGN Economic Moat
Premium
XNAS:REGN Stewardship
Premium
 
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
SHOOTER ERIC M
  2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS INC [REGN]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (Month/Day/Year)
02/23/2012
(Street)

TARRYTOWN, NY 10591
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/23/2012   C(1)   10,000 A $ 0 10,000 I GRAT self
Common Stock 02/23/2012   S   9,600 D $103.51(2) 400 I GRAT self
Common Stock 02/23/2012   S   400 D $104.05(3) 0 I GRAT self
Common Stock 02/23/2012   C(1)   10,000 A $ 0 10,000 I GRAT spouse
Common Stock 02/23/2012   S   9,600 D $103.51(2) 400 I GRAT spouse
Common Stock 02/23/2012   S   400 D $104.05(3) 0 I GRAT spouse
Common Stock               5,000 I by Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class A Stock $ 0 02/23/2012   C(1)     10,000   (4)   (4) Common Stock 10,000 $ 0 10,000 I GRAT self
Class A Stock $ 0 02/23/2012   C(1)     10,000   (4)   (4) Common Stock 10,000 $ 0 10,000 I GRAT spouse
Class A Stock $ 0 (1)               (1)   (1) Common Stock 36,911   36,911 I by Trust(5)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
SHOOTER ERIC M
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
  X      

Signatures

 /s/**Eric M. Shooter   02/24/2012
** Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events.
(2) Represents volume-weighted average price of sales of 9,600 shares of Company stock on February 23, 2012 at prices ranging from $103.01 to $103.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the GRAT on February 23, 2012 at each separate price.
(3) Represents volume-weighted average price of sales of 400 shares of Company stock on February 23, 2012 at prices ranging from $104.01 to $104.12. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the GRAT on February 23, 2012 at each separate price.
(4) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
(5) The reporting person and his spouse are co-trustees and beneficiaries of the Shooter Family Trust.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

XNAS:REGN Regeneron Pharmaceuticals Inc Insider Activity 4 Filling

Regeneron Pharmaceuticals Inc XNAS:REGN Stock - Get Insider Activity SEC Filing of Regeneron Pharmaceuticals Inc XNAS:REGN stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

XNAS:REGN Regeneron Pharmaceuticals Inc Insider Activity 4 Filing - 2/23/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XNAS:REGN Regeneron Pharmaceuticals Inc Insider Activity 4 Filing - 2/21/2012  |  Next: XNAS:REGN Regeneron Pharmaceuticals Inc Insider Activity 4 Filing - 2/6/2012